--- title: "GT Biopharma (GTBP) news: going concern and offering" url: "https://aibio.space/companies/gt-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "GTBP going concern, offering, convertible notes, lawsuit and settlement news: GT Biopharma gets Nasdaq minimum bid price notice, has until May 19, 2026 to…" --- GTBP GT Biopharma, Inc. NASDAQ · United States # GT Biopharma (GTBP) news GTBP going concern, offering and convertible notes news Legal · 2026-08-14 ## [GT Biopharma sued by four convertible note holders over undelivered conversion shares](https://aibio.space/news/gt-biopharma-sued-four-convertible-note-holders-undelivered-conversion/) GT Biopharma is the only defendant named in New York suits by Z-One, Silberfein, DiPietro and the Werthman Trust. Z-One's claims were dismissed and appealed. The other three are in settlement talks. ## Latest GT Biopharma news 1. 2026-03-02 Distress [GT Biopharma issues non-reliance notice, will restate June and September 2025 quarterly financials](https://aibio.space/news/gt-biopharma-issues-non-reliance-notice-will-restate-june-september/) On March 1, 2026 the audit committee concluded the quarterly reports contained an error: Greenshoe Rights from a May 2025 private placement required liability classification. GT Biopharma (Nasdaq: GTBP) will file Forms 10-Q/A. 2. 2025-11-26 Listings [GT Biopharma gets Nasdaq minimum bid price notice, has until May 19, 2026 to regain compliance](https://aibio.space/news/gt-biopharma-gets-nasdaq-minimum-bid-price-notice-has-until-may-19/) Nasdaq told GT Biopharma on November 20, 2025 that its stock had closed below $1 for 30 consecutive business days. The company has until May 19, 2026 to regain compliance, and its last annual report carried a going-concern warning alongside a $13.2 million net loss. 3. 2025-05-27 Financings [GT Biopharma enlarges preferred stock private placement to $5,950,000.00](https://aibio.space/news/gt-biopharma-enlarges-preferred-stock-private-placement-5-950-000-00/) A new purchaser joined the Series L 10% Convertible Preferred deal, which now carries an aggregate purchase price of $5,950,000.00. Buyers also hold greenshoe rights for up to $21,616,514 more. ## GT Biopharma at a glance - **Ticker**: GTBP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $5.0 million ### Related companies - [Evelo Biosciences](https://aibio.space/companies/evelo-biosciences/) OTC: EVLO - [Skinvisible](https://aibio.space/companies/skinvisible/) OTC: SKVI - [Dogwood Therapeutics](https://aibio.space/companies/dogwood-therapeutics/) NASDAQ: DWTX - [Seaport Therapeutics](https://aibio.space/companies/seaport-therapeutics/) NASDAQ: SPTX - [Palisade Bio](https://aibio.space/companies/palisade-bio/) NASDAQ: PALI - [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) NASDAQ: SNOA - [Reviva Pharmaceuticals Holdings](https://aibio.space/companies/reviva-pharmaceuticals/) OTC: RVPH - [Indivior Pharmaceuticals](https://aibio.space/companies/indivior-pharmaceuticals/) NASDAQ: INDV ### Also on NASDAQ - [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) KYTX - [ESTABLISHMENT LABS HOLDINGS INC.](https://aibio.space/companies/establishment-labs/) ESTA - [Envoy Medical](https://aibio.space/companies/envoy-medical/) COCH - [Syndax Pharmaceuticals](https://aibio.space/companies/syndax-pharmaceuticals/) SNDX - [Creative Medical Technology Holdings](https://aibio.space/companies/creative-medical-technology/) CELZ - [Summit Therapeutics](https://aibio.space/companies/summit-therapeutics/) SMMT ## GT Biopharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$3.5 million](https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/) | [$5.8 million](https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/) | | Net income (loss) | [-$28.4 million](https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/) | [-$13.2 million](https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/) | | Cash from operations | [-$12.9 million](https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/) | [-$12.9 million](https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/) | | Cash and equivalents | [$6.8 million](https://www.sec.gov/Archives/edgar/data/109657/000149315226037988/) | [$4.0 million](https://www.sec.gov/Archives/edgar/data/109657/000149315226009126/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about GT Biopharma Has GT Biopharma issued a going-concern warning? Our latest story on this, dated Nov 26, 2025: "GT Biopharma gets Nasdaq minimum bid price notice, has until May 19, 2026 to regain compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gt-biopharma-gets-nasdaq-minimum-bid-price-notice-has-until-may-19/). Has GT Biopharma raised money recently? Our latest story on this, dated Mar 2, 2026: "GT Biopharma issues non-reliance notice, will restate June and September 2025 quarterly financials". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gt-biopharma-issues-non-reliance-notice-will-restate-june-september/). Has GT Biopharma sold convertible notes? Our latest story on this, dated Aug 14, 2026: "GT Biopharma sued by four convertible note holders over undelivered conversion shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gt-biopharma-sued-four-convertible-note-holders-undelivered-conversion/). Is GT Biopharma involved in a lawsuit? Our latest story on this, dated Aug 14, 2026: "GT Biopharma sued by four convertible note holders over undelivered conversion shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gt-biopharma-sued-four-convertible-note-holders-undelivered-conversion/). Has GT Biopharma settled a lawsuit? Our latest story on this, dated Aug 14, 2026: "GT Biopharma sued by four convertible note holders over undelivered conversion shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gt-biopharma-sued-four-convertible-note-holders-undelivered-conversion/). What is the ticker symbol of GT Biopharma? GT Biopharma, Inc. trades under the ticker GTBP on NASDAQ. Where is GT Biopharma listed? GT Biopharma, Inc. is listed on NASDAQ. What is the SEC CIK of GT Biopharma? The SEC Central Index Key (CIK) for GT Biopharma, Inc. is 109657. Its filings are on SEC EDGAR. How many shares does GT Biopharma have outstanding? 45,109,497 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is GT Biopharma listed under? Our directory records GT Biopharma, Inc. under United States. What does GT Biopharma do? Our directory classifies GT Biopharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of GT Biopharma? The ISIN recorded for GT Biopharma, Inc. is US36254L4077. Does aibio.space cover GT Biopharma? aibio.space lists GT Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is GT Biopharma incorporated? SEC records list its state or country of incorporation as DE. Is GT Biopharma profitable? GT Biopharma, Inc. reported a net loss of $28.4 million for the fiscal year ended Dec 31, 2025, and used $12.9 million of cash in operations, per its annual report to the SEC. ## Investor discussion: GT Biopharma Members talk about GT Biopharma (GTBP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at GT Biopharma, newest first. Each line links the filing it comes from. 1. 2026-09-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315226044309/form8-k.htm) 2. 2026-09-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315226042672/form8-k.htm) 3. 2026-09-03 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315226041333/form8-k.htm) 4. 2026-08-14 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315226038446/form8-k.htm) 5. 2026-07-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315226031922/formdef14a.htm) 6. 2026-06-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315226029362/formpre14a.htm) 7. 2026-05-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/form8-k.htm) 8. 2026-03-02 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315226008442/form8-k.htm) 9. 2025-11-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315225025162/form8-k.htm) 10. 2025-05-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000164117225012481/form8-k.htm) 11. 2025-05-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/form8-k.htm) 12. 2025-04-04 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000164117225002750/form8-k.htm) 13. 2024-12-23 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315224051873/forms-1.htm) 14. 2024-11-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315224047994/form8-k.htm) 15. 2024-11-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/109657/000149315224045892/form10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GTBP on TradingView](https://www.tradingview.com/symbols/NASDAQ-GTBP/). ## SEC filings and registration - **SEC name**: GT Biopharma, Inc. - **CIK**: 109657 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: GTBP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 505 MONTGOMERY STREET, SAN FRANCISCO, CA, 94111 - **Phone**: (800) 304-9888 - **Shares outstanding**: 45,109,497 as of 2026-08-10 (10-Q filed 2026-08-14) - **Former names**: GT Biopharma, Inc.; OXIS INTERNATIONAL INC ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/109657/000149315226046861/formdef14a.htm) filed 2026-10-13 - [S-1](https://www.sec.gov/Archives/edgar/data/109657/000149315226046618/forms-1.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/109657/000149315226044309/form8-k.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/109657/000149315226043562/form8-k.htm) filed 2026-09-21 - [8-K](https://www.sec.gov/Archives/edgar/data/109657/000149315226042672/form8-k.htm) filed 2026-09-15 - [8-K](https://www.sec.gov/Archives/edgar/data/109657/000149315226041333/form8-k.htm) filed 2026-09-03 - [8-K](https://www.sec.gov/Archives/edgar/data/109657/000149315226038446/form8-k.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/109657/000149315226037988/form10-q.htm) filed 2026-08-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000109657), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details GT Biopharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GTBP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: GT Biopharma, Inc. - **Ticker**: GTBP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US36254L4077 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GTBP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/gt-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "GT Biopharma (GTBP) news: going concern and offering", 2026-10-31, https://aibio.space/companies/gt-biopharma/